(1) Liraglutide is a long-acting @entity6757 derivative, designed for once daily administration in type II @entity6 @entity1 . To investigate the effects of liraglutide on glycemic control and beta-cell mass in @entity35 models of @entity9608 , studies were performed in male Zucker @entity6 fatty (ZDF) @entity35 and in 60% pancreatectomized @entity35 . (2) When liraglutide was dosed s.c. at 150 microg kg-1 b.i.d. for 6 weeks in ZDF @entity35 6-8 weeks of age at study start, @entity6 development was markedly attenuated. Blood @entity413 was approximately 12 mm lower compared to vehicle (P<0.0002), and plasma insulin was 2-3-fold higher during a normal 24-h feeding period (P<0.001). Judged by pair feeding, approximately 53% of the antihyperglycemic effect observed on 24-h @entity413 profiles was mediated by a @entity448 , which persisted throughout the study and averaged 16% (P<0.02). (3) Histological analyses revealed that beta-cell mass and proliferation were significantly lower in prediabetic animals still normoglycemic after 2 weeks treatment compared to vehicle-treated animals that had begun to develop @entity6 . When the treatment period was 6 weeks, the liraglutide-treated animals were no longer completely normoglycemic and the beta-cell mass was significantly increased compared to overtly @entity6 vehicle-treated animals, while beta-cell proliferation was unaffected. (4) In the experiments with 60% pancreatectomized @entity35 , 8 days treatment with liraglutide resulted in a significantly lower @entity413 excursion in response to oral @entity413 compared to vehicle treatment. Again, part of the antihyperglycemic effect was due to reduced food intake. No effect of liraglutide on beta-cell mass was observed in these virtually normoglycemic animals. (5) In conclusion, treatment with liraglutide has marked antihyperglycemic effects in rodent models of @entity9608 , and the in vivo effect of liraglutide on beta-cell mass may in part depend on the metabolic state of the animals.

GLP-1 derivative liraglutide in @entity35 with XXXX : influence of metabolic state on beta-cell mass dynamics.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes'] @entity9608 :: ('MESH:D007340', 'Disease') :: ['beta-cell deficiencies'] @entity448 :: ('MESH:D000855', 'Disease') :: ['reduction in food intake'] @entity6757 :: ('100125288', 'Gene') :: ['GLP-1'] @entity35 :: ('10116', 'Species') :: ['rat', 'rats'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity9608 :: (MESH:D007340,Disease) :: ['beta-cell deficiencies']
